many patients do not have durable response. Additional approaches to promote CPI-mediated anticancer immunity could meet this therapeutic need1. The mode of action of CPIs is based on reinvigorating preexistent tumor
The combination of G and the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab (atezo), which has a complementary mode of action to anti-CD20 antibodies, has shown activity in R/R FL (Palomba et al. Hematol Oncol 2017). Atezo-G-LEN has the potential to enhance anti-tumor ...